이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Gufic Biosciences 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Pranav Choksi

최고 경영자

₹2.0m

총 보상

CEO 급여 비율	98.1%
CEO 임기	20.1yrs
CEO 소유권	7.2%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	8.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Pranav Choksi 의 보수는 Gufic Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	₹861m
Dec 31 2023	n/a	n/a	₹842m
Sep 30 2023	n/a	n/a	₹823m
Jun 30 2023	n/a	n/a	₹793m
Mar 31 2023	₹2m	₹2m	₹797m
Dec 31 2022	n/a	n/a	₹819m
Sep 30 2022	n/a	n/a	₹826m
Jun 30 2022	n/a	n/a	₹857m
Mar 31 2022	₹2m	₹2m	₹958m
Dec 31 2021	n/a	n/a	₹884m
Sep 30 2021	n/a	n/a	₹829m
Jun 30 2021	n/a	n/a	₹769m
Mar 31 2021	₹6m	₹2m	₹442m
Dec 31 2020	n/a	n/a	₹305m
Sep 30 2020	n/a	n/a	₹243m
Jun 30 2020	n/a	n/a	₹123m
Mar 31 2020	₹5m	₹2m	₹227m
Dec 31 2019	n/a	n/a	₹243m
Sep 30 2019	n/a	n/a	₹232m
Jun 30 2019	n/a	n/a	₹249m
Mar 31 2019	₹2m	₹2m	₹219m
Dec 31 2018	n/a	n/a	₹164m
Sep 30 2018	n/a	n/a	₹168m
Jun 30 2018	n/a	n/a	₹164m
Mar 31 2018	₹2m	₹2m	₹165m

보상 대 시장: Pranav 의 총 보상 ($USD 24.44K ) Indian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 267.13K ).

보상과 수익: Pranav 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Pranav Choksi (41 yo)

20.1yrs

테뉴어

₹2,040,900

보상

Mr. Pranav Jayesh Choksi has been an Executive Whole Time Director of Gufic Biosciences Ltd. since June 25, 2004 and serves as its Chief Executive Officer. Mr. Choksi serves as Chief Executive Officer & Wh...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jayesh Choksi	Chairman & MD	24.9yrs	₹4.04m	24.62% ₹ 9.0b
Pranav Choksi	CEO & Whole Time Director	20.1yrs	₹2.04m	7.25% ₹ 2.6b
Pankaj Gandhi	Whole-Time Director	10.9yrs	₹1.59m	데이터 없음
Dilip Ghosh	Additional Whole Time Director	3.7yrs	₹2.14m	0.072% ₹ 26.1m
Shreyas Patel	Non Executive Independent Director	9.9yrs	₹70.00k	0.0026% ₹ 942.0k
Gopal Daptari	Independent Director	7.7yrs	₹70.00k	데이터 없음
Balram Singh	Non-Executive & Non Independent Director	6.2yrs	데이터 없음	데이터 없음
Anu Aurora	Independent Director	4.6yrs	₹70.00k	데이터 없음

8.8yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: 509079 의 이사회는 경험(평균 재직 기간 7.6 년)으로 간주됩니다.

Gufic Biosciences 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Gufic Biosciences Limited Announces Cessation of Rabi Sahoo as Independent Director and Chairman of Stakeholders Relationship Committee and Member of Audit Committee

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

Insufficient new directors

Gufic Biosciences Limited, Annual General Meeting, Sep 02, 2022

Recent updates

Gufic Biosciences Limited Announces Cessation of Rabi Sahoo as Independent Director and Chairman of Stakeholders Relationship Committee and Member of Audit Committee

Investor sentiment improves as stock rises 19%

Gufic Biosciences Limited Proposes Recommendation of Final Dividend for the Financial Year 2023-24

Full year 2024 earnings released: EPS: ₹8.74 (vs ₹8.22 in FY 2023)

Third quarter 2024 earnings released: EPS: ₹2.23 (vs ₹2.10 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹2.39 (vs ₹2.09 in 2Q 2023)

Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited

Upcoming dividend of ₹0.10 per share

Gufic Biosciences Limited to Report Q2, 2024 Results on Nov 14, 2023

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Shareholder dilution

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

First quarter 2024 earnings released: EPS: ₹2.13 (vs ₹2.17 in 1Q 2023)

Gufic Biosciences Limited to Report Q1, 2024 Results on Aug 11, 2023

Investor sentiment improves as stock rises 18%

Gufic Biosciences Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Full year 2023 earnings released: EPS: ₹8.22 (vs ₹9.89 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹2.10 (vs ₹2.17 in 3Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹0.10 per share

First quarter 2023 earnings released: EPS: ₹2.17 (vs ₹3.22 in 1Q 2022)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Gufic Biosciences Limited, Annual General Meeting, Sep 02, 2022

Gufic Biosciences Limited to Report Q1, 2023 Results on Aug 11, 2022

Investor sentiment improved over the past week

Gufic Biosciences Limited Launches New Drug Delivery System

Full year 2022 earnings released: EPS: ₹9.89 (vs ₹4.56 in FY 2021)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Now 21% undervalued

Gufic Biosciences Limited Receives Permission from CDSCO to Manufacture and Sale Isavuconazonium Sulfate API and Finished Formulation Isavuconazole for Injection 200 Mg/Vial

Now 21% undervalued

Gufic Biosciences Limited Receives DCGI Nod for Thymosin Alpha - 1

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹2.41 (vs ₹2.10 in 2Q 2021)

Upcoming dividend of ₹0.10 per share

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹4.56 (vs ₹2.94 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: ₹109

Third quarter 2021 earnings released: EPS ₹1.69 (vs ₹0.90 in 3Q 2020)

Gufic Biosciences Limited to Report Q3, 2021 Results on Feb 08, 2021

New 90-day high: ₹132

Second quarter 2021 earnings released: EPS ₹2.10

Market bids up stock over the past week

Market bids up stock over the past week

New 90-day high: ₹103

Upcoming Dividend of ₹0.05 Per Share

First quarter earnings released

Full year earnings released - EPS ₹2.94

Gufic Biosciences Limited to Report Q4, 2020 Results on Jul 31, 2020

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령